참고문헌 (31)

1. Circulation Mozaffarian 131 e29 2015 10.1161/CIR.0000000000000152 Heart disease and stroke statistics-2015 update: a report from the American Heart Association 

   상세보기

2. Am J Epidemiol Austin 160 407 2004 10.1093/aje/kwh236 Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review 

   상세보기

3. World J Cardiol Hendrani 8 201 2016 10.4330/wjc.v8.i2.201 Dyslipidemia management in primary prevention of cardiovascular disease: current guidelines and strategies 

   

4. Lancet Cholesterol Treatment Trialists 385 1397 2015 10.1016/S0140-6736(14)61368-4 Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials 

   상세보기

5. J Am Coll Cardiol Stone 63 2889 2014 10.1016/j.jacc.2013.11.002 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 

   상세보기

6. Eur Heart J Catapano 37 2999 2016 10.1093/eurheartj/ehw272 ESC/EAS Guidelines for the Management of Dyslipidaemias 

   상세보기

7. Am J Cardiol Stein 100 1387 2007 10.1016/j.amjcard.2007.06.029 Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia 

   상세보기

8. FDA. Crestor label. 2013. 

9. Hellenic J Cardiol Daskalopoulou 45 288 2004 Ezetimibe: A new class of cholesterol lowering drugs 

10. Vasc Health Risk Manag Phan 8 415 2012 Ezetimibe therapy: mechanism of action and clinical update 

11. Am J Cardiol Bays 108 523 2011 10.1016/j.amjcard.2011.03.079 Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study) 

    상세보기

12. Am J Cardiol Ballantyne 99 673 2007 10.1016/j.amjcard.2006.10.022 Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study) 

    상세보기

13. Am J Med Bangalore 120 713 2007 10.1016/j.amjmed.2006.08.033 Fixed-dose combinations improve medication compliance: a meta-analysis 

    상세보기

14. Int J Clin Pharmacol Ther Migoya 44 83 2006 10.5414/CPP44083 Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects 

    상세보기

15. Clin Ther Li 29 2194 2007 10.1016/j.clinthera.2007.10.005 Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study 

    상세보기

16. Clin Drug Investig Chu 32 791 2012 10.1007/s40261-012-0013-5 Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects 

    상세보기

17. Int J Clin Pharmacol Ther Trabelsi 50 741 2012 Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions 

    상세보기

18. FDA. Zetia label. 2012. 

19. Korean J Fam Med Sang Sung 25 46 2004 The effect of atorvastatin on serum lipid levels among patients with hypercholesterolemia 

20. Am J Cardiovasc Drugs Kostapanos 10 11 2010 10.2165/13168600-000000000-00000 Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia 

    상세보기

21. Pharmacol Ther Shitara 112 71 2006 10.1016/j.pharmthera.2006.03.003 Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions 

    상세보기

22. Eur J Clin Pharmacol Birmingham 71 329 2015 10.1007/s00228-014-1800-0 Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States 

    상세보기

23. Curr Med Res Opin Reyderman 21 1171 2005 10.1185/030079905X46386 The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe 

    상세보기

24. Clin Ther Martin 25 2822 2003 10.1016/S0149-2918(03)80336-3 Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers 

    상세보기

25. Am J Cardiol McTaggart 87 28B 2001 10.1016/S0002-9149(01)01454-0 Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor 

    상세보기

26. Atheroscler Suppl McTaggart 4 9 2003 10.1016/S1567-5688(03)00004-7 Comparative pharmacology of rosuvastatin 

    상세보기

27. Clin Pharmacokinet Kosoglou 44 467 2005 10.2165/00003088-200544050-00002 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions 

    상세보기

28. Clin Ther Ezzet 23 871 2001 10.1016/S0149-2918(01)80075-8 A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe 

    상세보기

29. Drug Metab Dispos Patrick 30 430 2002 10.1124/dmd.30.4.430 Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects 

    상세보기

30. Curr Med Res Opin Kosoglou 20 1185 2004 10.1185/030079904125004213 Pharmacodynamic interaction between ezetimibe and rosuvastatin 

    상세보기

31. Guidance for Industry, Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs-General Considerations 2014